{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:50:28Z","timestamp":1790059828643,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008662","name":"Joachim Herz Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010856","name":"Texas A and M International University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1337508"],"award-info":[{"award-number":["1337508"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.bmcl.2019.07.001","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T14:41:36Z","timestamp":1562078496000},"page":"2112-2115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria"],"prefix":"10.1016","volume":"29","author":[{"given":"Keith D.","family":"Combrink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Ramirez","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Spring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schmidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Elizondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronilo","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant","family":"De Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian P.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2019.07.001_b0005","doi-asserted-by":"crossref","unstructured":"Brown-Elliott BA, Philley JV. In Rapidly Growing Mycobacteria, Microbiology Spectrum, Schlossberg, D. Ed., 2017 Jan;5(1), 703\u2013717. doi: 10.1128\/microbiolspec.TNMI7-0027-2016.","DOI":"10.1128\/microbiolspec.TNMI7-0027-2016"},{"key":"10.1016\/j.bmcl.2019.07.001_b0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.bmcl.2019.07.001_b0015","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1128\/AAC.02448-14","article-title":"Lack of antimicrobial bactericidal activity in mycobacterium abscessus","volume":"58","author":"Maurer","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2019.07.001_b0020","doi-asserted-by":"crossref","first-page":"e00155","DOI":"10.1128\/AAC.00155-17","article-title":"Rifabutin is active against Mycobacterium abscessus complex","volume":"61","author":"Aziz","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2019.07.001_b0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/BF00615223","article-title":"Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects","volume":"34","author":"Perucca","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2019.07.001_b0030","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/clinids\/21.3.594","article-title":"Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease","volume":"21","author":"Griffith","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.bmcl.2019.07.001_b0035","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1128\/AAC.42.10.2590","article-title":"Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus","volume":"42","author":"Aubry-Damon","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2019.07.001_b0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijantimicag.2005.09.015","article-title":"Association of rpoB mutations with rifampicin resistance in Mycobacterium avium","volume":"27","author":"Obata","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bmcl.2019.07.001_b0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1574-6968.1996.tb08515.x","article-title":"108 Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis","volume":"144","author":"Taniguchi","year":"1996","journal-title":"FEMS Microbiol Lett"},{"issue":"2","key":"10.1016\/j.bmcl.2019.07.001_b0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jac\/dkw466","article-title":"Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591","volume":"72","author":"Rominski","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.bmcl.2019.07.001_b0055","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1128\/AAC.39.4.1007","article-title":"Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation","volume":"39","author":"Dabbs","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.bmcl.2019.07.001_b0060","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1073\/pnas.0711939105","article-title":"Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr","volume":"105","author":"Baysarowich","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.bmcl.2019.07.001_b0065","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nchembio.2568","article-title":"Insights into the biogenesis, function, and regulation of ADP-ribosylation","volume":"14","author":"Cohen","year":"2018","journal-title":"Nat Chem Biol"},{"issue":"2","key":"10.1016\/j.bmcl.2019.07.001_b0070","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bmcl.2006.10.016","article-title":"New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases","volume":"17","author":"Combrink","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2019.07.001_b0075","series-title":"Susceptibility testing of mycobacteria, norcadiae, and other aerobic actinomycetes; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2011"},{"issue":"2","key":"10.1016\/j.bmcl.2019.07.001_b0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nprot.2007.521","article-title":"Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances","volume":"3","author":"Wiegand","year":"2008","journal-title":"Nat Protoc"},{"key":"10.1016\/j.bmcl.2019.07.001_b0085","unstructured":"A diagram of the plate layout as well as pictures of the zones of inhibition for each compound can be found in the supplemental material."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19304469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19304469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:32:16Z","timestamp":1760772736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X19304469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":17,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0960894X19304469"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.07.001","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}